Endo International plc announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for collagenase clostridium histolyticum (CCH) for the treatment

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In